NCT06724198 is a NA clinical trial of Psyllium husk in Low Anterior Resection Syndrome, sponsored by Sykehuset Telemark.

Who is sponsoring NCT06724198?

NCT06724198 is sponsored by Sykehuset Telemark.

What drugs are being tested in NCT06724198?

Interventions in NCT06724198: Psyllium husk.

What condition does NCT06724198 study?

NCT06724198 studies Low Anterior Resection Syndrome, Quality of Life (QOL).

Is NCT06724198 still recruiting?

NCT06724198 is currently active, enrolled. Last updated 9 July 2025.

Last reviewed 2025-07-09 · How we verify

NCT06724198

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bowel Dysfunction After Low Rectal Resection. An Pilot Study Using Psyllium Husk In Rectal Cancer Patients.

Active, enrolled NA Last updated 9 July 2025

What this trial tests

NA trial testing Psyllium husk in Low Anterior Resection Syndrome in 20 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 January 2025

Primary endpoint
1 July 2025

1 September 2025

Quick facts

Lead sponsor	Sykehuset Telemark
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 January 2025
Primary completion	1 July 2025
Estimated completion	1 September 2025
Sites	1 location across Norway

Drugs / interventions tested

Psyllium husk — full drug profile →

Conditions studied

Low Anterior Resection Syndrome — all drugs for Low Anterior Resection Syndrome →
Quality of Life (QOL) — all drugs for Quality of Life (QOL) →

Sponsor

Sykehuset Telemark — full company profile →

Who can join

18 and older, any sex, with Low Anterior Resection Syndrome or Quality of Life (QOL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rectal cancer constitutes 1/3 of more than 4500 annually diagnosed cases of colorectal (CRC) in Norway. With the advances in radiochemotherapy, and surgical techniques, the long-term survival rate is increasing after surgery regardless of the rising incidences, with a 73% 5-year survival rate in Norway (89% for stage I-III cancer). Low anterior resection (LAR) is the most commonly performed surgical procedure with curative intent with over 500 procedures per year in Norway alone. 80 % of patients subjected to LAR suffer from the LAR syndrome (LARS) which includes grades of bowel incontinence, urgency and tenesmus contributing to reduced quality of life (QoL). Suggested means of management have been advocated without preceding randomized trials. Psyllium husk has been suggested as a nutritional supplement for symptom reduction in patients suffering from LARS, but data is limited and no larger, randomized studies regarding its effect on patients with low anterior resection syndrome have been conducted. In this pilot study preceeding a placebo-controlled RCT, the investigators aim to improve documentation of a proposed management strategy. The investigators anticipate that a reduction in intestinal symptomburden will increase QoL for this large patientgroup.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of psyllium husk on low anterior resection syndrome after rectal cancer surgery-a pilot prospective cohort study.
Holte SS, Avaliani N, Hoff G, Kazaryan AM, et al · · 2025 · PMID 41446326 · DOI 10.3389/fsurg.2025.1686486

Verify or expand the search:

Other recruiting trials for Low Anterior Resection Syndrome

Currently open trials in the same condition.

NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT06424522 — A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Canc · NA · recruiting
NCT06758830 — Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. · Phase 2, PHASE3 · recruiting
NCT06222255 — The Safety and Efficacy of Transanal Irrigation in Patients With Sleep Disturbance From Low Anterior Resection Syndrome · NA · recruiting
NCT05943444 — Comparison of Postoperative Anal Function Between Parks and Bacon Techniques in Low Rectal Cancer · NA · recruiting

Other Sykehuset Telemark trials

Trials by the same sponsor.

NCT05227729 — Descending Aorta Blood Flow to Guide Fluid Therapy During Surgery · completed
NCT04763720 — Implementing Dyadic Developmental Psychotherapy (DDP) - Evaluation Research · enrolling by invitation
NCT05138055 — The NOrwegian Tick-borne Encephalitis Study · active not recruiting
NCT04514003 — The Corona and COVID-19 Study in Telemark and Agder · active not recruiting
NCT04219020 — Pain Burden in Children and Adolescents With Cerebral Palsy · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06724198 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sykehuset Telemark
Last refreshed: 9 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06724198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing